血液学の最新論文 | Hematopaseo

血液専門医と医療関係者のための情報サイト「ヘマトパセオ」

血液学の最新論文（2019年1月リリース分）New reports on Hematology

Leukemia

Blood Highs and lows of minimal residual disease in CLL. 133(5):386-388 Stephens DM
Blood Acute myeloid leukemia induces protumoral p16INK4a-driven senescence in the bone marrow microenvironment. 133(5):446-456 Abdul-Aziz AM, Sun Y, Hellmich C, Marlein CR, Mistry J, Forde E, Piddock RE, Shafat MS, Morfakis A, Mehta T, Di Palma F, Macaulay I, Ingham CJ, Haestier A, Collins A, Campisi J, Bowles KM, Rushworth SA
Blood Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. 133(5):494-497 Langerak AW, Ritgen M, Goede V, Robrecht S, Bahlo J, Fischer K, Steurer M, Trněný M, Mulligan SP, Mey UJM, Trunzer K, Fingerle-Rowson G, Humphrey K, Stilgenbauer S, Böttcher S, Brüggemann M, Hallek M, Kneba M, van Dongen JJM
Blood How I treat infant leukemia. 133(3):205-214 Brown P, Pieters R, Biondi A
Blood PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. 133(3):280-284 Passet M, Boissel N, Sigaux F, Saillard C, Bargetzi M, Ba I, Thomas X, Graux C, Chalandon Y, Leguay T, Lengliné E, Konopacki J, Quentin S, Delabesse E, Lafage-Pochitaloff M, Pastoret C, Grardel N, Asnafi V, Lhéritier V, Soulier J, Dombret H, Clappier E; Group for Research on Adult ALL (GRAALL)
Blood Combinations or sequences of targeted agents in CLL: is the whole greater than the sum of its parts (Aristotle, 360 BC)? 133(2):121-129 Sarraf Yazdy M, Mato AR, Cheson BD
Blood How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. 133(2):130-136 Ravandi F
Blood Loss of the selective autophagy receptor p62 impairs murine myeloid leukemia progression and mitophagy. 133(2):168-179 Nguyen TD, Shaid S, Vakhrusheva O, Koschade SE, Klann K, Thölken M, Baker F, Zhang J, Oellerich T, Sürün D, Derlet A, Haberbosch I, Eimer S, Osiewacz HD, Behrends C, Münch C, Dikic I, Brandts CH
Blood Relapsed NPM1 mutated acute myeloid leukemia with PDGFRA rearrangement. 133(2):181 Toruner GA, Thakral B
Blood Neutrophilic leukemoid reaction associated with plasma cell neoplasm mimicking chronic neutrophilic leukemia. 133(2):182 Xie W, Xu J
Blood Venetoclax in AML: aiming for “just right”. 133(1):3-4 Michaelis LC
Blood Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. 133(1):7-17 DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, Frankfurt O, Konopleva M, Wei AH, Kantarjian HM, Xu T, Hong WJ, Chyla B, Potluri J, Pollyea DA, Letai A
Haematologica Novel insights into the role of aberrantly expressed MNX1 (HLXB9) in infant acute myeloid leukemia. 104(1):1-3 Schwaller J
Haematologica Gemtuzumab ozogamicin in acute myeloid leukemia: act 2, with perhaps more to come. 104(1):7-9 Hitzler J, Estey E
Haematologica Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia. 104(1):9-12 Vitale C, Ferrajoli A
Haematologica Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome. 104(1):59-69 Stomper J, Ihorst G, Suciu S, Sander PN, Becker H, Wijermans PW, Plass C, Weichenhan D, Bissé E, Claus R, Lübbert M
Haematologica Transcriptional activation of the miR-17-92 cluster is involved in the growth-promoting effects of MYB in human Ph-positive leukemia cells. 104(1):82-92 Spagnuolo M, Regazzo G, De Dominici M, Sacconi A, Pelosi A, Korita E, Marchesi F, Pisani F, Magenta A, Lulli V, Cordone I, Mengarelli A, Strano S, Blandino G, Rizzo MG, Calabretta B
Haematologica Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. 104(1):93-101 Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE
Haematologica 2-Bromopalmitate targets retinoic acid receptor alpha and overcomes all-trans retinoic acid resistance of acute promyelocytic leukemia. 104(1):102-112 Lu Y, Yan JS, Xia L, Qin K, Yin QQ, Xu HT, Gao MQ, Qu XN, Sun YT, Chen GQ
Haematologica Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. 104(1):113-119 Lambert J, Pautas C, Terré C, Raffoux E, Turlure P, Caillot D, Legrand O, Thomas X, Gardin C, Gogat-Marchant K, Rubin SD, Benner RJ, Bousset P, Preudhomme C, Chevret S, Dombret H, Castaigne S
Haematologica Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group. 104(1):120-127 Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M
Haematologica Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion. 104(1):128-137 Ohki K, Kiyokawa N, Saito Y, Hirabayashi S, Nakabayashi K, Ichikawa H, Momozawa Y, Okamura K, Yoshimi A, Ogata-Kawata H, Sakamoto H, Kato M, Fukushima K, Hasegawa D, Fukushima H, Imai M, Kajiwara R, Koike T, Komori I, Matsui A, Mori M, Moriwaki K, Noguchi Y, Park MJ, Ueda T, Yamamoto S, Matsuda K, Yoshida T, Matsumoto K, Hata K, Kubo M, Matsubara Y, Takahashi H, Fukushima T, Hayashi Y, Koh K, Manabe A, Ohara A; Tokyo Children’s Cancer Study Group (TCCSG)
Haematologica Feasibility and efficacy of addition of individualized-dose lenalidomide to chlorambucil and rituximab as first-line treatment in elderly and FCR-unfit patients with advanced chronic lymphocytic leukemia. 104(1):147-154 Kater AP, van Oers MHJ, van Norden Y, van der Straten L, Driessen J, Posthuma WFM, Schipperus M, Chamuleau MED, Nijland M, Doorduijn JK, Van Gelder M, Hoogendoorn M, De Croon F, Wittebol S, Kerst JM, Marijt EWA, Raymakers RAP, Schaafsma MR, Dobber JA, Kersting S, Levin MD; HOVON CLL study group
Haematologica Impact of FLT3-ITD length on prognosis of acute myeloid leukemia. 104(1):e9-e12 Liu SB, Dong HJ, Bao XB, Qiu QC, Li HZ, Shen HJ, Ding ZX, Wang C, Chu XL, Yu JQ, Tao T, Li Z, Tang XW, Chen SN, Wu DP, Li L, Xue SL
Haematologica Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. 104(1):e13-e16 Biondi A, Cario G, De Lorenzo P, Castor A, Conter V, Leoni V, Gandemer V, Pieters R, Stary J, Escherich G, Campbell M, Attarbaschi A, Li CK, Vora A, Bradtke J, Saha V, Valsecchi MG, Schrappe M
Haematologica Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma. 104(1):e17-e20 De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P
Haematologica Spatial clonal evolution leading to ibrutinib resistance and disease progression in chronic lymphocytic leukemia. 104(1):e38-e41 Kiss R, Alpár D, Gángó A, Nagy N, Eyupoglu E, Aczél D, Matolcsy A, Csomor J, Mátrai Z, Bödör C
J Clin Oncol Initial Diagnostic Work-Up of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists and American Society of Hematology Guideline. 37(3):239-253 de Haas V, Ismaila N, Advani A, Arber DA, Dabney RS, Patel-Donelly D, Kitlas E, Pieters R, Pui CH, Sweet K, Zhang L
J Clin Oncol Optimizing Cardiovascular Care in Children With Acute Myeloid Leukemia to Improve Cancer-Related Outcomes. 37(1):1-6 Armenian SH, Ehrhardt MJ
Lancet Haematol Closing in on targeted therapy for acute myeloid leukaemia. 6(1):e1 The Lancet Haematology
Lancet Haematol 10-day decitabine schedule in acute myeloid leukaemia: no extra bang for the buck. 6(1):e6-e7 Cashen AF
Lancet Haematol Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. 6(1):e29-e37 Short NJ, Kantarjian HM, Loghavi S, Huang X, Qiao W, Borthakur G, Kadia TM, Daver N, Ohanian M, Dinardo CD, Estrov Z, Kanagal-Shamanna R, Maiti A, Benton CB, Bose P, Alvarado Y, Jabbour E, Kornblau SM, Pemmaraju N, Jain N, Gasior Y, Richie MA, Pierce S, Cortes J, Konopleva M, Garcia-Manero G, Ravandi F
Lancet Haematol Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study. 6(1):e38-e47 Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Bazemore J, Miskin HP, Sportelli P, Stampleman L, Maegawa R, Rueter J, Boruchov AM, Arnason JE, Jacobson CA, Jacobsen ED, Fisher DC, Brown JR; Blood Cancer Research Partnership of the Leukemia and Lymphoma Society
Lancet Oncol Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. 20(1):43-56 Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW
Leukemia Genetic predisposition to B-cell acute lymphoblastic leukemia at 14q11.2 is mediated by a CEBPE promoter polymorphism. 33(1):1-14 Studd JB, Yang M, Li Z, Vijayakrishnan J, Lu Y, Yeoh AE, Paulsson K, Houlston RS
Leukemia Long-term recovery of quality of life and physical function over three years in adult survivors of acute myeloid leukemia after intensive chemotherapy. 33(1):15-25 Timilshina N, Breunis H, Tomlinson GA, Brandwein JM, Buckstein R, Durbano S, Alibhai SMH
Leukemia Profiling of aberrant DNA methylation in acute myeloid leukemia reveals subclasses of CG-rich regions with epigenetic or genetic association. 33(1):26-36 Gebhard C, Glatz D, Schwarzfischer L, Wimmer J, Stasik S, Nuetzel M, Heudobler D, Andreesen R, Ehninger G, Thiede C, Rehli M
Leukemia Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. 33(1):37-51 Barghout SH, Patel PS, Wang X, Xu GW, Kavanagh S, Halgas O, Zarabi SF, Gronda M, Hurren R, Jeyaraju DV, MacLean N, Brennan S, Hyer ML, Berger A, Traore T, Milhollen M, Smith AC, Minden MD, Pai EF, Hakem R, Schimmer AD
Leukemia Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. 33(1):52-63 Boudreaux SP, Duren RP, Call SG, Nguyen L, Freire PR, Narayanan P, Redell MS, Conneely OM
Leukemia Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. 33(1):64-74 Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M
Leukemia Antibodies conjugated with viral antigens elicit a cytotoxic T cell response against primary CLL ex vivo. 33(1):88-98 Schneidt V, Ilecka M, Dreger P, van Zyl DG, Fink S, Mautner J, Delecluse HJ
Leukemia Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells. 33(1):181-190 Tasian SK, Casas JA, Posocco D, Gandre-Babbe S, Gagne AL, Liang G, Loh ML, Weiss MJ, French DL, Chou ST
Leukemia Dnmt1 links BCR-ABLp210 to epigenetic tumor stem cell priming in myeloid leukemia. 33(1):249-278 Vicente-Dueñas C, González-Herrero I, Sehgal L, García-Ramírez I, Rodríguez-Hernández G, Pintado B, Blanco O, Criado FJG, Cenador MBG, Green MR, Sánchez-García I
Leukemia The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells. 33(1):262-266 Li Z, He S, Look AT
Leukemia Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. 33(1):266-270 Aldoss I, Capelletti M, Park J, Pistofidis RS, Pillai R, Stiller T, Sanchez JF, Forman SJ, Ghobrial IM, Krishnan A

Lymphoma

Myeloma

SCT

HSC

Anemia

Bone marrow failure

ITP

このキーワードに関連した論文はありません